Progressive supranuclear palsy

Progressive supranuclear palsy (PSP) is a rare brain disease that steadily damages movement, balance, and thinking. Researchers are testing valproic acid, a drug already used for epilepsy and mood disorders, to see if it can protect brain cells by blocking an enzyme involved in t…

This phase 2 trial tests whether glycerol phenylbutyrate (GPB) can slow corticobasal syndrome (CBS), a rare and fast-progressing brain disease. 32 adults with CBS will receive either GPB or a placebo for 26 weeks. The main goal is to see if GPB lowers levels of a nerve damage mar…

This completed Phase 2b/3 trial tested the drug AMX0035 in 139 people with progressive supranuclear palsy (PSP), a rare brain disease that causes problems with balance, movement, and thinking. The study compared the drug to a placebo to see if it could slow the disease. The resul…

This study tested a drug called TPN-101 in 42 people with progressive supranuclear palsy (PSP), a rare brain disease that affects movement and thinking. The main goal was to see if the drug is safe and tolerable over 48 weeks. Researchers also looked at how the drug moves in the …

This study tested a drug called GV1001 in 78 people with Progressive Supranuclear Palsy (PSP), a rare brain disease that affects movement and thinking. Participants received daily injections of either a low dose, a higher dose, or a placebo for 6 months. The goal was to see if th…

This early-stage trial tested a drug called NIO752 in 59 people with progressive supranuclear palsy (PSP), a rare brain disorder that affects movement and balance. The drug was given as a spinal injection to see if it is safe and how the body processes it. The main goal was to ch…

This study looked at the long-term safety of a daily injection called GV1001 in people with progressive supranuclear palsy (PSP), a rare brain disease that affects movement and balance. It included 67 patients who had already completed a previous GV1001 study. Researchers monitor…

Researchers are testing whether tissue samples taken during a routine colon exam can help tell apart Parkinson's disease from two similar conditions: multiple system atrophy and progressive supranuclear palsy. The study includes 34 people aged 50 to 80, some with these conditions…

This early-phase study tests two new imaging drugs, [18F]ABBV-964i and [18F]ABBV-965i, designed to light up tau protein buildup in the brain during a PET scan. Tau buildup is linked to Progressive Supranuclear Palsy (PSP), a rare movement and thinking disorder. The trial includes…

This study tested whether a single infusion of zoledronic acid (Reclast) can prevent fractures in men and women aged 60 and older with Parkinson's disease or related conditions. Over 2,700 participants were randomly assigned to receive either the drug or a placebo, and were follo…

Researchers at Baylor College of Medicine are studying whether weekly art therapy can ease symptoms and improve quality of life for people with progressive supranuclear palsy (PSP), a rare brain disorder that affects movement, balance, and eye control. About 20 participants with …

This study tested two sleep medications (suvorexant and zolpidem) against a placebo in 40 adults with Progressive Supranuclear Palsy (PSP). The goal was to see if targeting the brain's wake-promoting system could improve sleep quality and daytime well-being. Each person tried all…

This study tested a new way of caring for people with Parkinson's disease. The goal was to help 214 participants achieve their personal goals and improve their quality of life. The approach involved proactive, integrated care and patient empowerment, compared to standard care.

This completed study looked for specific gene patterns in the blood that could help diagnose Parkinson's disease and distinguish it from similar conditions. Researchers analyzed blood samples and brain scans from 219 people with Parkinson's or related disorders. The goal is to de…

This completed study looked for genetic and environmental factors that increase the risk of developing Parkinson's disease. Researchers compared DNA and lifestyle data from over 2,200 people, including Parkinson's patients, people with related brain diseases, and healthy voluntee…

This completed study looked at how the prefrontal cortex helps us understand analogies and categories. Researchers used brain scans, EEG, and magnetic stimulation in 130 healthy volunteers and patients with frontotemporal dementia or progressive supranuclear palsy. The goal was t…